|Table of Contents|

A review of drug therapy of advanced non-small cell lung cancer with performance status≥2

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 11
Page:
2164-2169
Research Field:
Publishing date:

Info

Title:
A review of drug therapy of advanced non-small cell lung cancer with performance status≥2
Author(s):
WANG Yanning1; ZHOU Yujie2; MIAO Liyun2
1.Clinical Stem Cell Center,Nanjing Drum Tower Hospital,Jiangsu Nanjing 210008,China;2.Department of Respiration,Nanjing Drum Tower Hospital,Jiangsu Nanjing 210008,China.
Keywords:
non-small cell lung cancer; performance status; drug treatment
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.11.035
Abstract:
The performance status(PS) score of lung cancer patients can effectively predict the treatment effect and guide the clinician's treatment options.Patients with PS≥2 accounted for approximately 30%~40% of the non-small cell lung cancer(NSCLC) patients.Due to the insufficient organ function status and the high incidence of adverse events,these patients are excluded from major clinical trials.At present,the most suitable chemotherapy regimen for this type of patients is still uncertain.Considering that immune and targeted therapies are better tolerated than chemotherapy,despite the lack of sufficient clinical data,these new treatment regimens are often used for unselected NSCLC patients with PS≥2.Here we review the results of existing clinical studies for reference.

References:

[1]CHEN W,SUN K,ZHENG R,et al.Cancer incidence and mortality in China ［J］.Journal of the National Cancer Center,2018,30(1):1-12.
[2]OKEN MM,CREECH RH,TORMEY DC,et al.Toxicity and response criteria of the Eastern Cooperative Oncology Group ［J］.American Journal of Clinical Oncology,1982,5(6):649-655.
[3]LILENBAUM RC,CASHY J,HENSING TA,et al.Prevalence of poor performance status in lung cancer patients:implications for research ［J］.Journal of Thoracic Oncology,2008,3(2):125-129.
[4]RUCKDESCHEL JC,FINKELSTEIN DM,ETTINGER DS,et al.A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer ［J］.Journal of Clinical Oncology,1986,4(1):14-22.
[5]SWEENEY CJ,ZHU J,SANDLER AB,et al.Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594:a Phase II trial in patients with metastatic nonsmall cell lung carcinoma ［J］.Cancer,2001,92(10):2639-2647.
[6]PLANCHARD D,POPAT S,KERR K,et al.Metastatic non-small cell lung cancer:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up published correction appears in Ann Oncol ［J］.Annals of Oncology,2018,29(Suppl 4):iv192-iv237.
[7]HANNA N,JOHNSON D,TEMIN S,et al.Systemic therapy for stage IV non-small-cell lung cancer:American Society of Clinical Oncology Clinical Practice Guideline update published correction appears in J Clin Oncol ［J］.Journal of Thoracic Oncology,2017,35(30):3484-3515.
[8]O' BRIEN ME,SOCINSKI MA,POPOVICH AY,et al.Randomized phase III trial comparing single-agent paclitaxel Poliglumex(CT-2103,PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer ［J］.Journal of Thoracic Oncology,2008,3(7):728-734.
[9]CALIFANO R,GRIFFITHS R,LORIGAN P,et al.Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status(PS) 2 patients with advanced non-small cell lung cancer(NSCLC):DOC PS2 trial.Manchester lung cancer group ［J］.Lung Cancer,2011,73(3):338-344.
[10]HATA A,KATAKAMI N,FUJITA S,et al.A phase II study of pemetrexed monotherapy in chemo-naive Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer(HANSHIN Oncology Group 002) ［J］.Cancer Chemotherapy and Pharmacology,2015,75(6):1267-1272.
[11]LANGER C,LI S,SCHILLER J,et al.Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients:ECOG 1599 ［J］.Journal of Clinical Oncology,2007,25(4):418-423.
[12]LANGER CJ,O' BYRNE KJ,SOCINSKI MA,et al.Phase III trial comparing paclitaxel poliglumex(CT-2103,PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer ［J］.Journal of Clinical Oncology,2008,3(6):623-630.
[13]LILENBAUM R,WANG X,GU L,et al.Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2:CALGB 30402 ［J］.Journal of Clinical Oncology,2009,27(27):4487-4491.
[14]GRONBERG BH,BREMNES RM,FLOTTEN O,et al.Phase III study by the Norwegian lung cancer study group:pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer ［J］.Journal of Clinical Oncology,2009,27(19):3217-3224.
[15]GAJRA A,KARIM NA,MULFORD DA,et al.Nab-paclitaxel-based therapy in underserved patient populations:The ABOUND.PS2 study in patients with NSCLC and a performance status of 2 ［J］.Frontiers in Oncology,2018,8:253.
[16]NAKASHIMA K,AKAMATSU H,MURAKAMI H,et al.Carboplatin plus nab-paclitaxel in performance status 2 patients with advanced non-small-cell lung cancer ［J］.Anticancer Research,2019,39(3):1463-1468.
[17]LILENBAUM RC,HERNDON JE,LIST MA,et al.Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer:the cancer and leukemia group B(study 9730) ［J］.Journal of Clinical Oncology,2005,23(1):190-196.
[18]ZUKIN M,BARRIOS CH,PEREIRA JR,et al.Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2 ［J］.Journal of Clinical Oncology,2013,31(23):2849-2853.
[19]KOSMIDIS PA,DIMOPOULOS MA,SYRIGOS K,et al.Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2:a prospective randomized phase II study of the Hellenic Cooperative Oncology Group ［J］.Journal of Thoracic Oncology,2007,2(2):135-140.
[20]REYNOLDS C,OBASAJU C,SCHELL MJ,et al.Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer ［J］.Journal of Clinical Oncology,2009,27(34):5808-5815.
[21]MORABITO A,GEBBIA V,DI MAIO M,et al.Randomized phase III trial of gemcitabine and cisplatin vs gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2:the CAPPA-2 study ［J］.Lung Cancer,2013,81(1):77-83.
[22]MORTH C,VALACHIS A.Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2:a literature-based meta-analysis of randomized studies ［J］.Lung Cancer,2014,84(3):209-214.
[23]BRONTE G,ROLFO C,PASSIGLIA F,et al.What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis ［J］.Critical Reviews in Oncology/Hematology,2015,95(3):306-317.
[24]LUO L,HU Q,JIANG JX,et al.Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2:a meta-analysis ［J］.Asia-Pacific Journal of Clinical Oncology,2015,11(3):253-261.
[25]INOUE A,KOBAYASHI K,USUI K,et al.First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy published correction appears in J Clin Oncol ［J］.Journal of Clinical Oncology,2009,27(9):1394-1400.
[26]IWAMA E,GOTO Y,MURAKAMI H,et al.Survival analysis for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status treated with alectinib:Updated results of lung oncology group in Kyushu 1401 ［J］.Oncologist,2020,25(4):306-318.
[27]LILENBAUM R,AXELROD R,THOMAS S,et al.Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 ［J］.Journal of Clinical Oncology,2008,26(6):863-869.
[28]MORERE JF,BRECHOT JM,WESTEEL V,et al.Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3(IFCT-0301 study) ［J］.Lung Cancer,2010,70(3):301-307.
[29]LEE SM,KHAN I,UPADHYAY S,et al.First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy(TOPICAL):a double-blind,placebo-controlled,phase 3 trial ［J］.Lancet Oncology,2012,13(11):1161-1170.
[30]GRIGORESCU AC,BALA C.Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis,advanced non-small cell lung cancer patients ［J］.Journal of the Balkan Union of Oncology,2013,18(1):188-194.
[31]MICHAEL M,PAVLAKIS N,CLINGAN P,et al.A multi-centre randomized,open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer ［J］.Oncology Reports,2012,28(3):763-767.
[32]MICHAEL M,WHITE SC,ABDI E,et al.Multicenter randomized,open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC ［J］.Asia-Pacific Journal of Clinical Oncology,2015,11(1):4-14.
[33]RIGGS H,JALAL SI,BAGHDADI TA,et al.Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer,a phase II study of the Hoosier Oncology Group:LUN04-77 ［J］.Clinical Lung Cancer,2013,14(3):224-229.
[34]HERBST RS,ANSARI R,BUSTIN F,et al.Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy(BeTa):a double-blind,placebo-controlled,phase 3 trial ［J］.Lancet,2011,377(9780):1846-1854.
[35]SPIGEL DR,HAINSWORTH JD,JOSEPH MJ,et al.Randomized phase 2 trial of pemetrexed,pemetrexed/bevacizumab,and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2 ［J］.Cancer,2018,124(9):1982-1991.
[36]BERSANELLI M,BRIGHENTI M,BUTI S,et al.Patient performance status and cancer immunotherapy efficacy:a meta-analysis ［J］.Medical Oncology,2018,35(10):132.
[37]DALL'OLIO FG,MAGGIO I,MASSUCCI M,et al.ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data ［J］.Lung Cancer,2020,145:95-104.
[38]FELIP E,ARDIZZONI A,CIULEANU T,et al.CheckMate 171:A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer,including ECOG PS 2 and elderly populations ［J］.European Journal of Cancer,2020,127:160-172.
[39]SPIGEL DR,MCCLEOD M,JOTTE RM,et al.Safety,efficacy,and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer,including patients aged 70 years or older or with poor performance status(CheckMate 153) ［J］.Journal of Thoracic Oncology,2019,14(9):1628-1639.
[40]JUERGENS RJ,CHU Q,ROTHENSTEIN J,et al.CheckMate 169:Safety/efficacy of nivolumab in Canadian pretreated advanced NSCLC(including elderly and PS 2) patients ［J］.Journal of Thoracic Oncology,2017,11:S2426-S2427.
[41]MIDDLETON G,BROCK K,SAVAGE J,et al.Pembrolizumab in patients with non-small-cell lung cancer of performance status 2(PePS2):a single arm,phase 2 trial ［J］.The Lancet Respiratory Medicine,2020,8(9):895-904.
[42]BARLESI F,AUDIGIER-VALETTE C,FELIP E,et al.OA04.02 CheckMate 817:First-line nivolumab+ipilimumab in patients with ECOG PS 2 and other special populations with advanced NSCLC ［J］.Journal of Thoracic Oncology,2019,14(10):S214-S215.
[43]SHIBAKI R,MURAKAMI S,SHINNO Y,et al.Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer ［J］.Cancer Immunology,Immunotherapy,2020,69(7):1229-1236.
[44]FACCHINETTI F,MAZZASCHI G,BARBIERI F,et al.First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status ［J］.European Journal of Cancer,2020,130:155-167.

Memo

Memo:
吴阶平医学基金会临床科研专项资助基金（编号：320.6750.17242）
Last Update: 2023-04-28